249420 - Ildong Pharm

249420 Summary

Biopharma

Stock Price & Overview

₩15,030 -70 (-0.46%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩15,030 ≈ US$11 · Market cap ₩0.5tn (≈ $340m)

249420 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	566.9	614.9	600.8	637.7	560.1	561.8	517.5	503.9	460.7	201.3	—
Cost of Revenue	347.2	381.5	386.9	401.4	340.7	323.4	285.1	248.8	234.4	104.0	—
Gross Profit	219.8	233.5	213.8	236.3	219.4	238.4	232.4	255.2	226.2	97.3	—
Selling, General & Administrative	164.7	174.1	172.8	199.9	178.4	171.6	185.2	180.4	167.5	70.0	—
Operating Income	19.5	13.1	-53.9	-73.5	-55.5	6.6	-1.4	28.3	25.4	14.8	—
Finance Income	25.5	23.9	6.5	18.3	0.6	0.4	0.4	0.5	0.3	0.1	—
Finance Costs	14.8	30.3	45.6	43.5	87.4	10.1	5.2	3.6	3.8	1.7	—
Pretax Income	31.8	-10.7	-94.3	-119.8	-141.2	-9.7	-22.6	16.4	20.4	14.0	—
Income Tax Expense	8.1	1.7	-13.3	22.3	-40.2	3.3	-9.2	3.7	0.6	1.4	—
Net Income	23.7	-12.4	-81.0	-142.2	-101.0	-13.0	-13.4	12.7	19.8	12.6	—
Total Comprehensive Income	37.6	-16.6	-52.5	-132.3	-103.6	1.7	-15.2	10.5	22.1	11.9	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	573.0	589.0	611.3	655.8	709.0	605.3	612.7	564.7	563.9	550.4	—
Current Assets	222.0	247.0	235.7	282.0	301.6	233.2	233.4	210.5	205.0	218.7	—
Cash & Cash Equivalents	64.8	72.3	53.3	52.1	135.6	85.6	90.0	75.9	39.9	19.9	—
Inventories	100.5	87.9	84.6	98.2	82.6	89.2	69.7	53.2	60.0	61.2	—
Trade Receivables	54.1	71.0	66.5	61.8	59.3	55.1	71.2	78.0	103.9	136.7	—
Non-current Assets	351.1	342.1	375.6	373.8	407.4	372.0	379.4	354.2	358.8	331.7	—
Property, Plant & Equipment	199.0	201.8	239.3	255.3	247.8	256.4	259.5	227.5	228.3	236.3	—
Intangible Assets	—	—	—	47.1	66.6	63.1	69.6	88.2	99.1	76.0	—
Total Liabilities	333.5	430.0	437.0	457.6	548.4	350.7	359.8	287.8	279.6	281.9	—
Current Liabilities	231.0	276.0	346.5	316.3	364.1	185.0	211.8	162.9	157.4	142.5	—
Non-current Liabilities	102.5	154.0	90.5	141.3	184.2	165.7	148.0	124.9	122.1	139.4	—
Total Equity	239.5	159.1	174.3	198.2	160.6	254.5	252.9	276.8	284.3	268.4	—
Share Capital	31.6	28.1	28.1	26.8	23.8	23.8	22.7	21.6	19.6	17.8	—
Retained Earnings	105.7	-50.9	-58.5	-211.1	-82.0	14.9	-4.9	17.4	26.6	11.8	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	19.0	28.3	-36.6	-53.5	-11.4	19.4	41.4	66.6	73.7	19.2	—
Cash from Investing Activities	-2.3	18.5	-20.4	-26.4	-43.4	-18.4	-14.0	-22.6	-47.9	-13.8	—
Purchase of Property, Plant & Equipment	13.6	10.7	13.2	11.9	14.6	14.4	12.1	15.1	16.7	—	—
Cash from Financing Activities	-24.1	-27.9	58.2	-3.3	104.3	-4.6	-13.5	-7.9	-5.4	-0.1	—
Dividends Paid	0.1	0.1	0.2	0.1	—	—	8.6	7.8	5.4	—	—
Net Change in Cash	-7.4	18.9	1.2	-83.4	50.0	-4.4	14.0	36.0	20.0	5.3	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	147.9	142.0	147.0	145.5	138.5	136.0	155.7	155.9	152.1	151.1
Cost of Revenue	91.2	83.4	90.1	86.9	84.7	85.5	95.5	98.9	94.2	92.8
Gross Profit	56.7	58.6	56.9	58.5	53.8	50.5	60.3	57.0	57.9	58.3
Selling, General & Administrative	44.2	40.3	39.9	42.4	44.1	38.4	43.0	43.2	46.1	41.8
Operating Income	2.0	9.2	7.9	6.8	0.6	4.2	8.4	3.6	1.0	0.1
Finance Income	1.8	1.0	1.4	17.7	3.3	3.1	6.3	0.4	8.4	8.8
Finance Costs	1.8	1.9	2.2	3.9	2.9	5.7	9.9	4.3	10.0	6.0
Pretax Income	3.5	9.2	6.1	28.3	-3.8	1.1	-4.1	-7.2	-1.9	2.5
Income Tax Expense	-1.6	1.8	0.5	6.8	0.1	0.6	-7.0	2.0	2.3	4.4
Net Income	5.1	7.4	5.6	21.5	-3.9	0.5	2.9	-9.2	-4.2	-1.9
Total Comprehensive Income	9.6	6.7	12.7	23.9	0.9	0.2	-0.8	-8.0	-5.8	-2.0

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	560.5	562.1	573.0	573.9	583.8	574.5	589.0	590.5	604.7	600.9
Current Assets	218.6	221.9	222.0	222.4	243.6	237.3	247.0	256.1	241.5	233.7
Cash & Cash Equivalents	53.4	35.9	64.8	49.6	58.4	58.5	72.3	48.9	48.3	48.2
Inventories	95.9	103.1	100.5	99.5	98.2	94.8	87.9	88.3	93.7	85.8
Trade Receivables	59.2	56.5	54.1	58.6	74.0	69.9	71.0	70.2	72.2	67.7
Non-current Assets	341.9	340.2	351.1	351.5	340.2	337.2	342.1	334.4	363.2	367.2
Property, Plant & Equipment	193.8	196.8	199.0	199.3	196.5	199.7	201.8	206.4	235.2	237.7
Intangible Assets	—	—	—	—	—	—	—	36.7	37.9	39.6
Total Liabilities	310.9	322.1	333.5	347.0	423.6	415.2	430.0	433.0	438.3	428.7
Current Liabilities	218.0	223.5	231.0	243.4	315.8	306.8	276.0	284.1	318.7	279.7
Non-current Liabilities	93.0	98.6	102.5	103.6	107.7	108.4	154.0	148.9	119.6	149.0
Total Equity	249.6	240.0	239.5	226.8	160.2	159.2	159.1	157.4	166.4	172.2
Share Capital	31.6	31.6	31.6	31.6	28.1	28.1	28.1	28.1	28.1	28.1
Retained Earnings	119.6	111.9	105.7	95.0	67.1	70.1	-50.9	-70.5	-62.5	-59.4

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	10.5	-2.7	16.4	11.3	-7.6	-1.1	18.4	6.6	7.0	-3.6
Cash from Investing Activities	14.4	-20.0	10.1	-8.7	-3.3	-0.4	-3.2	27.8	-5.7	-0.4
Purchase of Property, Plant & Equipment	1.1	2.6	2.0	7.3	1.7	2.7	2.6	2.6	2.6	2.9
Cash from Financing Activities	-7.5	-6.2	-11.3	-11.4	11.0	-12.3	8.2	-33.8	-1.1	-1.1
Dividends Paid	—	—	0.0	0.0	—	—	0.0	0.0	—	—
Net Change in Cash	17.4	-29.0	15.2	-8.8	0.0	-13.8	23.3	0.5	0.1	-5.1

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

249420 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	566.9	-7.8%	-3.8%	+0.2%	—
Operating income	19.5	+48.5%	—	+24.0%	—
Net income	23.7	—	—	—	—
EPS	₩749	—	—	—	—
Operating cash flow	19.0	-33.0%	—	-0.4%	—
Shareholders' equity	239.5	+50.6%	+6.5%	-1.2%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

249420 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Gross margin	38.8%	38.0%	35.6%	37.1%	39.2%	42.4%
Operating margin	3.4%	2.1%	-9.0%	-11.5%	-9.9%	1.2%
Net margin	4.2%	-2.0%	-13.5%	-22.3%	-18.0%	-2.3%
Return on equity	11.9%	-7.4%	-43.5%	-79.2%	-48.6%	-5.1%
Return on assets	4.1%	-2.1%	-12.8%	-20.8%	-15.4%	-2.1%
Operating cash flow / revenue	3.3%	4.6%	-6.1%	-8.4%	-2.0%	3.4%
Capex / revenue	2.4%	1.7%	2.2%	1.9%	2.6%	2.6%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 249420

Symbol	Last Price
085660Chabiotech Co., Ltd.	₩8,090 +2.1%
476060Onconic Therapeutics, Inc.	₩16,440 -3.9%
041960Komipharm International Co., Ltd.	₩9,710 +3.5%
317450Myungin Pharm	₩44,650 +0.0%
001060JW Pharmaceutical	₩27,500 +1.3%
456160G2GBIO, Inc.	₩37,950 +5.7%
019170Shinpoong Pharmaceutical Co., Ltd.	₩10,010 -0.9%
358570GI Innovation, Inc.	₩8,090 +6.2%
086900Medy-Tox, Inc.	₩69,600 +0.4%
397030April Bio Co., Ltd.	₩17,800 +6.1%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.